Latest Breaking News On - Astellas pharma us inc - Page 1 : comparemela.com

Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ Iveric Bio, An Astellas Company , today announced the U.S. Centers for Medicare and Medicaid Services.

Naoki okamuraMichael petroutsasIveric bioMedicaid servicesAstellas pharma incAstellas companyAstellas pharma us incUs centers for medicareHealthcare common procedure coding systemFocus area approach

Astellas Names Michael Petroutsas as Head of US Commercial

Astellas Names Michael Petroutsas as Head of US Commercial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark reisenauerClaus zielerAstellas pharma us incAstellas pharma incAstellas pharmaChief commercial officerUnited states commercialChief commercialSenior vice presidentOncology businessFocus area approach

Inflammation Has Little to No Effect on Safety, Effectiveness of Roxadustat for Anemia in CKD

According to a new systematic review and meta-analysis, roxadustat's efficacy remains consistent across varying inflammation levels in patients with chronic kidney disease.

United statesWeiru zhangAstellas pharma us incEuropean commissionInternational clinical trials registry platformCochrane libraryNutrition examinationNational clinical research centerNational healthDrug administrationGeriatric disordersZiangya hospitalNew drug applicationConfidence intervalRisk factorsClinical outcomesa systematic literature

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNaoki okamuraAhsan arozullahRoger danseyDrug administrationEuropean society for medical oncologyInternational agency for research on cancerMerck sharp dohme corpAstellas pharma us incMerck co incEuropean commissionCorporate communicationsEuropean medicines agency for padcevNational cancer institutePfizer incHead of oncology development

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on Jan. 26, 2024.

United statesNaoki okamuraAhsan arozullahRoger danseyEuropean medicines agencyPrnewswire astellas pharma incMerck sharp dohme corpCommittee for medicinal products human useMerck co incPfizer incAstellas pharma us incEuropean medicines agency for padcevEuropean commissionDrug administrationEuropean society for medical oncologyAmerican society of clinical oncology